Hepatocellular carcinoma: sorafenib: for once age is not an issue.

Dufour, Jean-François (2014). Hepatocellular carcinoma: sorafenib: for once age is not an issue. Nature reviews - gastroenterology & hepatology, 11(5), pp. 273-274. Nature Publishing Group 10.1038/nrgastro.2014.48

Full text not available from this repository. (Request a copy)

Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1759-5045

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

20 Apr 2015 15:15

Last Modified:

06 Nov 2015 09:42

Publisher DOI:

10.1038/nrgastro.2014.48

PubMed ID:

24686265

URI:

https://boris.unibe.ch/id/eprint/67296

Actions (login required)

Edit item Edit item
Provide Feedback